Scarica l'app Stockscreener
1.51
3.42%
0.05
Dopo l'orario di chiusura:
1.62
0.11
+7.28%
Precedente Chiudi:
$1.46
Aprire:
$1.42
Volume 24 ore:
1.23M
Relative Volume:
1.93
Capitalizzazione di mercato:
$193.23M
Reddito:
-
Utile/perdita netta:
$-35.47M
Rapporto P/E:
-2.8203
EPS:
-0.5354
Flusso di cassa netto:
$-124.27M
1 W Prestazione:
-15.88%
1M Prestazione:
-8.48%
6M Prestazione:
-41.02%
1 anno Prestazione:
-15.64%
Intervallo 1D:
$1.4055
$1.545
Intervallo di 1 settimana:
$1.4055
$2.03
Portata 52W:
$1.18
$4.44
Prokidney Corp Stock (PROK) Company Profile
Nome
Prokidney Corp
Settore
Industria
Telefono
336-999-7028
Indirizzo
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Confronta PROK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.51 | 193.23M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-30 | Iniziato | JP Morgan | Neutral |
| 2024-09-10 | Iniziato | Guggenheim | Buy |
| 2024-03-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-07-25 | Iniziato | BTIG Research | Buy |
| 2022-12-21 | Iniziato | Jefferies | Buy |
| 2022-11-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Iniziato | UBS | Buy |
| 2022-10-14 | Iniziato | Citigroup | Buy |
| 2022-09-23 | Iniziato | BofA Securities | Buy |
| 2022-09-02 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Prokidney Corp Borsa (PROK) Ultime notizie
ProKidney (NASDAQ:PROK) Shares Down 4.8%Here's What Happened - MarketBeat
Charles Schwab Investment Management Inc. Has $1.44 Million Holdings in ProKidney Corp. (NASDAQ:PROK) - MarketBeat
ProKidney (NASDAQ:PROK) Trading 5.9% HigherHere's What Happened - MarketBeat
Vigil Neuroscience (NASDAQ:VIGL) and ProKidney (NASDAQ:PROK) Head-To-Head Contrast - Defense World
JP Morgan Initiates Coverage of ProKidney (PROK) with Neutral Recommendation - MSN
ProKidney (NASDAQ:PROK) Trading 8.4% HigherWhat's Next? - MarketBeat
ProKidney (NASDAQ:PROK) Stock Price Up 5.4%Still a Buy? - MarketBeat
Suvretta Capital Management LLC Acquires 3,000,000 Shares of ProKidney Corp. (NASDAQ:PROK) - MarketBeat
ProKidney to Participate in Two Upcoming Conferences: - GlobeNewswire
ProKidney to Present at Evercore and Citi Healthcare Conferences in December | PROK Stock News - StockTitan
US Penny Stocks To Watch: 3 Picks With Market Caps Under $500M - Simply Wall St
The Best Laid Plans Of Mice And ProKidney… - The Rhino TImes
ProKidney purchases former Collins Aerospace facility, own HQ for $22.5M - The Business Journals
Future of development project promising hundreds of job now uncertain - MSN
ProKidney no longer coming to Greensboro, Chamber of Commerce confirms - MSN
ProKidney to buy two buildings in Winston-Salem. Announcement comes days after it listed Greensboro site for sale - Greensboro News & Record
ProKidney buys Winston-Salem land after passing on Greensboro deal - Business North Carolina
ProKidney puts its Greensboro factory site up for sale or lease - Winston-Salem Journal
ProKidney: Manufacturing expansion moving to W-S instead of Greensboro - The Business Journals
ProKidney lists Greensboro property for sale, leaving future in city uncertain - WFMYNews2.com
ProKidney lists building where it planned $458M investment for sale - The Business Journals
We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely - Simply Wall St
ProKidney’s Progress in FDA Approval and Financial Health - TipRanks
Prokidney Corp. Reports Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - Marketscreener.com
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - The Manila Times
ProKidney Reports Third Quarter 2024 Financial Results - GlobeNewswire
ProKidney Surges on FDA Backing for Phase 3 Study, Reports $406.8M Cash Position | PROK Stock News - StockTitan
Triad's public companies have gained millions in value since election - The Business Journals
Morgan Stanley's Strategic Reduction in ProKidney Corp Holdings - GuruFocus.com
ProKidney: Major Catalyst Is Too Far Away (NASDAQ:PROK) - Seeking Alpha
ProKidney to Participate in the Guggenheim Inaugural - GlobeNewswire
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference - The Manila Times
ProKidney (PROK) to Present at Guggenheim and Jefferies Healthcare Conferences | PROK Stock News - StockTitan
ProKidney amends Phase III protocol in light of Phase II results - MSN
Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
ProKidney CEO Bruce Culleton named to Triad Power 50 Five to Watch list - The Business Journals
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp - Yahoo Finance
Reviewing ProKidney (NASDAQ:PROK) and Innate Pharma (NASDAQ:IPHA) - Defense World
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate - Yahoo Finance
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
ProKidney Announces Five Abstracts Selected for - GlobeNewswire
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024 - Yahoo Finance
Stocks of ProKidney Corp (PROK) are poised to climb above their peers - SETE News
Gaining Ground: ProKidney Corp (PROK) Closes Lower at 1.70, Down -0.58 - The Dwinnex
PROK underperforms with a -1.16 decrease in share price - US Post News
ProKidney Corp (PROK) Becoming More Attractive for Investors - Knox Daily
PROK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
ProKidney to Participate in the UBS Virtual Organ Restoration Day - GlobeNewswire
Prokidney Corp Azioni (PROK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):